Src Family Kinase Inhibition as a Novel Strategy to Augment Melphalan-Based Regional Chemotherapy of Advanced Extremity Melanoma

[1]  K. Grossmann,et al.  Molecular testing in malignant melanoma , 2012, Diagnostic cytopathology.

[2]  M. Dewhirst,et al.  Bevacizumab-Induced Alterations in Vascular Permeability and Drug Delivery: A Novel Approach to Augment Regional Chemotherapy for In-Transit Melanoma , 2012, Clinical Cancer Research.

[3]  V. Sondak,et al.  Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma , 2011, British Journal of Cancer.

[4]  K. Flaherty,et al.  Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J. Montero,et al.  Inhibition of Src Family Kinases and Receptor Tyrosine Kinases by Dasatinib: Possible Combinations in Solid Tumors , 2011, Clinical Cancer Research.

[6]  D. Rimm,et al.  In vitro studies of dasatinib, its targets and predictors of sensitivity , 2011, Pigment cell & melanoma research.

[7]  S. Woodman,et al.  Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics. , 2010, Biochemical pharmacology.

[8]  Sin-Ho Jung,et al.  Sorafenib, a Multikinase Inhibitor, Enhances the Response of Melanoma to Regional Chemotherapy , 2010, Molecular Cancer Therapeutics.

[9]  C. Augustine,et al.  Inhibition of Poly(ADP-Ribose) Polymerase Enhances the Effect of Chemotherapy in an Animal Model of Regional Therapy for the Treatment of Advanced Extremity Malignant Melanoma , 2010, Annals of Surgical Oncology.

[10]  E. Haura,et al.  Src kinases as therapeutic targets for cancer , 2009, Nature Reviews Clinical Oncology.

[11]  G. Mills,et al.  Activity of dasatinib against L576P KIT mutant melanoma: Molecular, cellular, and clinical correlates , 2009, Molecular Cancer Therapeutics.

[12]  Hua Yu,et al.  Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma , 2009, Melanoma research.

[13]  M. Clynes,et al.  Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines , 2008, Journal of Translational Medicine.

[14]  M. Ross,et al.  Phase II trial of imatinib mesylate in patients with metastatic melanoma , 2008, British Journal of Cancer.

[15]  R. Petersen,et al.  Isolated Limb Infusion for In-Transit Malignant Melanoma of the Extremity: A Well-Tolerated but Less Effective Alternative to Hyperthermic Isolated Limb Perfusion , 2008, Annals of Surgical Oncology.

[16]  J. Olson,et al.  Gene Expression Signatures as a Guide to Treatment Strategies for In-Transit Metastatic Melanoma , 2008, Molecular Cancer Therapeutics.

[17]  P. Febbo,et al.  Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatment. , 2008, Cancer research.

[18]  A. D. Van den Abbeele,et al.  Major response to imatinib mesylate in KIT-mutated melanoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Yan Liu,et al.  Transactivation of vascular endothelial growth factor receptor-2 by interleukin-8 (IL-8/CXCL8) is required for IL-8/CXCL8-induced endothelial permeability. , 2007, Molecular biology of the cell.

[20]  C. Augustine,et al.  Defining regional infusion treatment strategies for extremity melanoma: comparative analysis of melphalan and temozolomide as regional chemotherapeutic agents , 2007, Molecular Cancer Therapeutics.

[21]  S. Rabbani,et al.  A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo. , 2007, Cancer research.

[22]  J. Homsi,et al.  The Src signaling pathway: a potential target in melanoma and other malignancies , 2007, Expert opinion on therapeutic targets.

[23]  D. Pinkel,et al.  Somatic activation of KIT in distinct subtypes of melanoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  K. Brown,et al.  A Phase II Trial of Isolated Limb Infusion With Melphalan and Dactinomycin for Regional Melanoma and Soft Tissue Sarcoma of the Extremity , 2006, Annals of Surgical Oncology.

[25]  M. Atkins,et al.  Multicenter Phase II trial of high‐dose imatinib mesylate in metastatic melanoma , 2006, Cancer.

[26]  O. Abdel-Wahab,et al.  Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine , 2006, Molecular Cancer Therapeutics.

[27]  D. Schadendorf,et al.  Lack of clinical efficacy of imatinib in metastatic melanoma , 2005, British Journal of Cancer.

[28]  Ping Chen,et al.  Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. , 2004, Journal of medicinal chemistry.

[29]  H. Friedman,et al.  Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma. , 2004, American journal of surgery.

[30]  J. Parsons,et al.  Src family kinases, key regulators of signal transduction , 2004, Oncogene.

[31]  N. Carragher,et al.  Src-Mediated Phosphorylation of Focal Adhesion Kinase Couples Actin and Adhesion Dynamics to Survival Signaling , 2004, Molecular and Cellular Biology.

[32]  J. Kirkwood,et al.  Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? , 2004, European journal of cancer.

[33]  Timothy J. Yeatman,et al.  A renaissance for SRC , 2004, Nature Reviews Cancer.

[34]  S. Ashley,et al.  Inhibition of Src Tyrosine Kinase Impairs Inherent and Acquired Gemcitabine Resistance in Human Pancreatic Adenocarcinoma Cells , 2004, Clinical Cancer Research.

[35]  G. Gallick,et al.  Src family kinases in tumor progression and metastasis , 2003, Cancer and Metastasis Reviews.

[36]  W. Kilarski,et al.  Inactivation of Src family kinases inhibits angiogenesis in vivo: implications for a mechanism involving organization of the actin cytoskeleton. , 2003, Experimental cell research.

[37]  H. Yoshiji,et al.  pp60c-src activation in lung adenocarcinoma. , 2003, European journal of cancer.

[38]  C. Szabó,et al.  The Therapeutic Potential of Poly(ADP-Ribose) Polymerase Inhibitors , 2002, Pharmacological Reviews.

[39]  M. Frame,et al.  Src in cancer: deregulation and consequences for cell behaviour. , 2002, Biochimica et biophysica acta.

[40]  P. Kam,et al.  Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma , 2002, Annals of Surgical Oncology.

[41]  L. Tentori,et al.  Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors. , 2002, Pharmacological research.

[42]  Heike Allgayer,et al.  Activation of Src kinase in primary colorectal carcinoma , 2002, Cancer.

[43]  F. Giancotti,et al.  A Requirement for Caveolin-1 and Associated Kinase Fyn in Integrin Signaling and Anchorage-Dependent Cell Growth , 1998, Cell.

[44]  J. Stockman.  KIT as a Therapeutic Target in Metastatic Melanoma , 2013 .

[45]  J. Q. Rosso,et al.  A Phase 2 Trial of Dasatinib in Advanced Melanoma , 2012 .